CLINUVEL PHARMACEUTICALS LIMITED

4.39%

$12.40

Market Cap $626.0M

Healthcare Biotechnology

Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on... Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run. Latest:...

Latest Threads

Tag

Subject

CUV

We're at $12!

10:57

5.4K

10:57

Last post Hotfire

5.4K

CUV

BANNED!!!

10:22

1.7K

10:22

Last post rpape1

1.7K

CUV

REPORT JUST DROPPED - Check this out!

31/07/25

12K

31/07/25

Last post Melon felon!

12K

CUV

Disc Medicine - Best comparison stock to Clinuvel

3 4 5

31/07/25

254

117K

31/07/25

Last post Steveenforce

254

117K

CUV

Ann: Presentation to BTIG Biotech Conference

30/07/25

2.2K

30/07/25

Last post alcar

2.2K

CUV

AI garbage

30/07/25

1.0K

30/07/25

Last post Melon felon!

1.0K

CUV

The Most Undervalued Stock on the ASX

8 9 10

30/07/25

553

196K

30/07/25

Last post OCM_

553

196K

CUV

Ann: Two Grounds of Appeal Upheld by NICE Panel

29/07/25

2.8K

29/07/25

Last post plaster

2.8K

See All Discussions

Timeline

Presentation to BTIG Biotech Conference
30 Jul 12:06	Share

Notification of cessation of securities - CUV
02 Jul 08:21	Share

German Non-deal Roadshow Presentation
24 Jun 08:45	Share

Ceasing to be a substantial holder
19 Jun 08:16	Share

Study confirms NB-UVB needed to activate repigmentation
18 Jun 09:35	Share

Becoming a substantial holder
18 Jun 08:19	Share

CLINUVEL management update
13 Jun 09:35	Share

SCENESSE successfully administered to paediatric EPP patient
13 Jun 08:58	Share

SCENESSE in Vitiligo - A Global Update
04 Jun 10:07	Share

SCENESSE EPP data featured at EADV Symposium
22 May 08:57	Share

Ceasing to be a substantial holder
09 May 08:24	Share

CUV recruits 200 patients in Phase III vitiligo trial CUV105
07 May 08:41	Share

Notification regarding unquoted securities - CUV
23 Apr 09:00	Share

Notification of cessation of securities - CUV
09 Apr 08:22	Share

Section 708A Cleansing Statement
07 Apr 08:55	Share

Application for quotation of securities - CUV
07 Apr 08:51	Share

Application for quotation of securities - CUV
07 Apr 08:49	Share

Change in substantial holding
01 Apr 19:43	Share

Notification of buy-back - CUV
27 Mar 09:04	Share

CLINUVEL renews share buy-back program
27 Mar 09:03	Share

Update - Notification of buy-back - CUV
27 Mar 08:58	Share

Positive preliminary results for PRENUMBRA Instant in stroke
26 Mar 09:15	Share

2025 American Academy of Dermatology Annual Meeting
24 Mar 09:19	Share

CLINUVEL management update
18 Mar 09:02	Share

CLINUVEL Unveils Vitiligo Program for AAD 2025
04 Mar 08:59	Share

CLINUVEL Investor Webinar
28 Feb 09:06	Share

Chair Letter to Shareholders
28 Feb 09:04	Share

Half Year Results Presentation
27 Feb 10:48	Share

Half Year Results Announcement
27 Feb 10:47	Share

Appendix 4D and Half Year Report
27 Feb 10:42	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $12.40		Change -0.570(4.39%)		Mkt cap ! $626.0M

Open	High	Low	Value	Volume
$13.02	$13.18	$12.37	$460.9K	36.35K

Buyers (Bids)

No.	Vol.	Price($)
1	117	$12.38

Sellers (Offers)

Price($)	Vol.	No.
$12.40	800	1

View Market Depth

No.	Vol.	Price($)
2	1055	12.410
2	159	12.390
2	159	12.380
3	169	12.370
3	165	12.360

Price($)	Vol.	No.
12.450	67	3
12.460	332	4
12.470	540	2
12.480	61	2
12.490	91	3

Last trade - 10.51am 01/08/2025 (20 minute delay)


Last $12.38		Change -0.570 ( 4.77 %)
Open	High	Low	Volume
$12.66	$12.80	$12.38	967
Last updated 11.07am 01/08/2025 ?

CUV (ASX) Chart

CLINUVEL PHARMACEUTICALS LIMITED

Latest Threads

Redcastle Resources Delivers Positive Scoping Study for Queen Alexandra

Timeline

Featured News

Latest Articles

Clinuvel shares dip, even as CEO comes back from temp leave

After Clinuvel's (ASX:CUV) CEO Dr. Philippe Wolgen took time off back in March to respond to an "acute medical condition," it wasn't...

Clinuvel stroke drug shows 'positive' results – but some adverse effects left unclear

Clinuvel shares jumped on Tuesday on higher volumes as the company reported a clinical trial win with its stroke drug, 'PRENUMBRA.'

British study shows Clinuvel drug effective on DNA of UV-damaged skin

Clinuvel Pharmaceuticals Ltd has reported final results of its study of the efficacy of afamelanotide to repair the DNA of damaged skin.

Buyers (Bids)

Sellers (Offers)

Codeifai looks to ride AI wave as Quantum Computing becomes a necessity

Prospect Resources: Replicating the success of Arcadia with ~1b tonne copper ore target

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

Top Stories

Featured News